Phase 1 Study of Everolimus Combined with Lutetium-177 Octreotate Radiopeptide Therapy of Advanced Low-Grade Neuroendocrine Tumours
نویسندگان
چکیده
منابع مشابه
A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.
BACKGROUND This was a two-stage, phase II trial of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor BEZ235 in patients with everolimus-resistant pancreatic neuroendocrine tumours (pNETs) (NCT01658436). PATIENTS AND METHODS In stage 1, 11 patients received 400 mg BEZ235 orally twice daily (bid). Due to tolerability concerns, a further 20 patients received BEZ235 3...
متن کاملMutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial
INTRODUCTION Finding the optimal management strategy for patients with advanced, metastatic neuroendocrine tumours (NETs) of the gastrointestinal tract and pancreas is a work in progress. Sunitinib and everolimus are currently approved for the treatment of progressive, unresectable, locally advanced or metastatic low-grade or intermediate-grade pancreatic NETs. However, mutation-targeted therap...
متن کاملTherapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma.
OBJECTIVE Hypoglycaemia poses a significant management challenge in patients with unresectable functional malignant insulinoma. Novel agents such as mammalian target of rapamycin (mTOR) inhibitors and radiolabelled peptides may be effective where there is failure of conventional therapy. DESIGN We present the cases of two men diagnosed with inoperable malignant insulinoma and hepatic metastas...
متن کاملProlonged Clinical Benefit of Everolimus Therapy in the Management of High-Grade Pancreatic Neuroendocrine Carcinoma
Treatment options for patients with high-grade pancreatic neuroendocrine tumors (pNET) are limited, especially for those with progressive disease and for those who experience treatment failure. Everolimus, an oral inhibitor of mammalian target of rapamycin (mTOR), has been approved for the treatment of patients with low- or intermediate-grade advanced pNET. In the randomized phase III RADIANT-3...
متن کامل1149psingle Center Experience of Everolimus Combined with Long-acting Octreotide in Patients (pts) with Pretreated Advanced Well Differentiated Neuroendocrine Tumours (nets) of Different Origin.
Methods: 33 pts with progressive well differentiated NETs (G1,G2) were treated with everolimus 10 mg q.d. combined with octreotide LAR 30-40 mg till progression or intolerable toxicity. All pts were evaluable for efficacy and toxicity. The mean age was 54 years (25-72), 11 male, 22 female. The most of pts had pancreatic NETs–13 (39%) pts. There were 19 (57,6%) NETs of foregut origin, 8 (24,2%) ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2012
ISSN: 0923-7534
DOI: 10.1016/s0923-7534(20)33732-7